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The molecular and cellular biology of lung
cancer: identifying novel therapeutic
strategies
Alison C.MacKinnon, Jens Kopatz, and Tariq Sethi*
Centre for Inflammation Research, Queens Medical Research Institute, University of Edinburgh,
47 Little France Crescent, Edinburgh EH16 4TJ, UK
Introduction: Lung cancer is the commonest fatal malignancy in the developed
world. Survival rates for lung cancer have not changed significantly over the
past 30 years.
Sources of data: This report is a systematic review of the literature on our
current understanding of lung cancer biology. Searches were carried out using
PUBMED. 1990–2010.
Areas of agreement: A concerted effort to reduce cigarette smoking and nicotine
addiction is required. A better understanding of the biology of lung cancer will
lead to the identification of earlier diagnostic markers and improved therapy.
Areas of controversy: How chronic inflammatory disorders such as COPD and
lung fibrosis contribute to lung cancer development is incompletely understood.
Growing Points: Developing novel biological agents to target lung cancer. New
microarray-based technologies provide new methods for predicting prognosis and
response to treatment.
Areas timely for developing research: Developing strategies to target lung cancer
stem cells may provide a novel approach for treating drug resistant disease.
Keywords: lung cancer/smoking/inflammation/genetics/chemotherapy/signal
transduction
Introduction
Lung cancer is the commonest fatal malignancy in the developed world
causing more than 1 million deaths/year. In the UK, lung cancer kills
over 37 000 people/year. Current therapies rarely cure the disease, the
high relapse rate coupled with delayed diagnosis results in a poor progno-
sis and the overall survival rate is about 10%. With the increase in ciga-
rette smoking in developing countries, especially India and China, lung
cancer will remain a major health problem for the foreseeable future.
British Medical Bulletin 2010; 95: 47–61
DOI:10.1093/bmb/ldq023
& The Author 2010. Published by Oxford University Press. All rights reserved.
For permissions, please e-mail: journals.permissions@oxfordjournals.org
Accepted: June 30, 2010
*Correspondence address.
Centre for Inflammation
Research, Queens Medical
Research Institute,
University of Edinburgh,
47 Little France Crescent,
Edinburgh EH16 4TJ, UK.
E-mail: t.sethi@ed.ac.uk
Published Online July 19, 2010
 by guest on June 21, 2013
http://bm
b.oxfordjournals.org/
D
ow
nloaded from
 
About 75–80% of lung cancers are caused by smoking. It is impor-
tant to reduce cigarette smoking, stop young people from starting and
help people stop through smoking cessation programmes and banning
smoking in public places. However, about 50% of all new lung cancers
are diagnosed in ex-smokers and 25% of all lung cancer cases in the
world occur in never smokers (defined as a lifetime exposure of less
than 100 cigarettes). Worldwide it is estimated that 15% of all lung
cancers in men and 53% of lung cancers in women are not due to ciga-
rette smoking. Lung cancer in never smokers would rank as the seventh
most common cause of cancer deaths worldwide and is more common
than deaths from cervical cancer or prostate cancer.1 Furthermore,
chronic inflammatory diseases of the lung such as chronic obstructive
pulmonary disease (COPD) and lung fibrosis are significant indepen-
dent risk factors for developing lung cancer.
In the UK, 50% of patients present with advanced disease and are
not amenable to curative treatment. Increasing public awareness of
symptoms and developing biomarkers for early detection may lead to
earlier diagnosis. The majority of lung cancers arise from epithelial
cells. The two most prevalent histological types of lung cancer are
non-small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma
(SCLC) causing 80% and 18% of all lung cancer, respectively. There
are three main subtypes of NSCLCs: squamous cell lung carcinoma,
adenocarcinoma and large cell lung carcinoma. A better understanding
of the molecular and cellular biology of lung cancer, the mechanisms
causing lung cancer in never smokers and defining the common mol-
ecular pathways by which chronic inflammatory diseases lead to the
initiation of lung cancer may identify biomarkers and screening tests,
in addition to identifying more effective therapeutic strategies and
targets.
Smoking and lung cancer
Cigarette smoke contains over 60 known carcinogens particularly poly-
cyclic aromatic hydrocarbons (e.g. benzo[a]pyrene) and nitrosamines.
Cytochrome P450 enzymes metabolically activate these polycyclic aro-
matic hydrocarbons and nitrosamines, which can then bind to DNA
leading to DNA adducts. Glutothione-S-tranferases protect against
DNA adduct formation by detoxifying carcinogen intermediates. DNA
adducts are mostly repaired; however, chronic DNA adduct formation
can lead to mutations in genes such as p53 that are central to lung
cancer initiation.2
Tobacco smoke also contains a large amount of free radical oxygen
that can cause oxidation of the DNA nucleobase guanine to form
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8-oxoguanine resulting in G to T substitutions and gene mutations.
8-Oxoguanine is repaired by 8-oxoguanine DNA N-glycosylase 1
(OGG1). Studies suggest that low OGG1 activity increases the risk of
lung cancer among smokers. Furthermore, OGG1 Ser326Cys genetic
polymorphisms influence the risk of lung cancer, the Cys/Cys genotype
is associated with an increased risk of lung cancer compared with the
Ser/Ser genotype among heavy smokers.3
Genetic studies have identified a nicotine dependence locus on
chromosome 15q24-25, which includes the aa5-a3-b4 nicotinic recep-
tor gene cluster. A polymorphism, which alters an amino acid in the
aa5 nicotinic receptor subunit also influences the risk for lung cancer,
COPD and vascular disease. In addition, nicotine inhibits apoptosis
and can act as a tumour promoter in lung epithelial cells. Varenicline is
a partial nicotinic receptor agonist, which reduces nicotine craving.
Buproprion inhibits noradrenaline and dopamine reuptake to improve
the cessation rates. Genetic profiling of individual smokers may identify
the most suitable pharmacologic agent to aid smoking cessation.4
Lung cancer in never smokers
The clinical presentation of lung cancer in never smokers is strikingly
different from that of smokers. Adenocarcinoma is the predominant
form of lung cancer in never smokers in contrast to smokers who
develop all major histological types of lung cancer. In patients less than
40 years old, adenocarcinoma was the commonest form of lung cancer
with a disproportionately high ratio of never smokers. In smokers, ade-
nocarcinoma occurs both centrally and in the peripheral airways;
however, adenocarcinoma in never smokers is predominantly found in
the peripheral airways. Lung cancer in never smokes is more common
in women than men. In South East Asia, over 80% of females with
lung cancer are never smokers compared with 15% in the USA.5 Lung
cancer patients, who are never smokers, present at an earlier age in
South East Asia, compared with the USA and Europe where lung
cancer is diagnosed at the same age as smokers. Studies suggest that
never smokers present with more advanced stage lung cancer but have
improved survival compared with smokers, independent of other prog-
nostic factors.6 It is unclear whether never smokers respond differently
to chemotherapy compared with current and former smokers, as
studies are conflicting.
Passive smoking, mainly due to spousal and workplace exposure, is
associated with a 10–15% increased risk of developing lung cancer
and urine metabolites of tobacco-specific carcinogens are detectable in
non-smokers passively exposed to cigarette smoke.7 Other risk factors
Advances in lung cancer biology
British Medical Bulletin 2010;95 49
 by guest on June 21, 2013
http://bm
b.oxfordjournals.org/
D
ow
nloaded from
 
including environmental, hormonal, genetic and viral may account
each year for about 3000–4000 deaths in the UK and about 16 000–
24 000 deaths in the USA. However, no single factor can explain the
development of lung cancer in never smokers.
Chronic inflammation and lung cancer
Chronic lung inflammation predisposes to lung cancer. There is a 4–5
times greater risk for developing lung cancer among those with COPD
independent of age or smoking history.8 Even among non-smokers, the
presence of emphysema on CT scan or a history of COPD is signifi-
cantly associated with an increased risk of developing lung cancer. In
never smokers, carrying the a1 anti-trypsin deficiency allele increases
the risk of lung cancer by 2.2-fold, with a significant increase in adeno-
carcinoma and squamous cell carcinoma.9 Furthermore, recent studies
have suggested that inhaled corticosteroids may reduce the risk of lung
cancer in patients with COPD.10 In addition, patients with scleroderma
who smoke are seven times more likely to develop lung cancer than
non-smokers and heavier smokers more likely to develop lung cancer
than light smokers. Peripheral lung tumours occur earlier after the
onset of scleroderma symptoms than bronchogenic tumours, reflecting
the inflammatory origin of these tumours.11 Idiopathic pulmonary
fibrosis and pneumoconiosis associated with silica exposure are associ-
ated with an independent increased risk of lung cancer. Evidence
suggests that recurrent injury and inflammation result in genetic altera-
tions that predispose to lung cancer, again smoking may play a signifi-
cant role.
Chronic infections such as hepatitis B or C virus and the Epstein–
Barr virus are associated with the development of cancer. The airways
of a healthy lung are sterile; however, microbial colonization and
associated inflammation develop early in the course of COPD and may
persist in ex-smokers with COPD. Failure of the innate immune system
in the lung in COPD allows the establishment of chronic infection.
Chronic infection further disrupts the innate lung defenses driving a
vicious circle of infection and inflammation in COPD. Experiments in
mice have shown that infecting the lung with non-typeable
Haemophilus influenza caused a COPD-like bronchial inflammation
that promotes lung cancer development.12 The co-existence of tubercu-
losis (TB) and lung cancer is well described. A study in India reported
that TB lesions, either active or healing, were found in the lungs of
30–33% of patients with bronchogenic tumours when compared with
7% in the general population.13 Repeated tissue damage and regener-
ation as a result of inhalation of environmental toxic pollutants such as
A. C. MacKinnon et al.
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exhaust fumes, and sulphur dioxide as well as microorganisms results
in lung injury and generation of reactive oxygen/nitrogen species (ROS/
RNS) such as superoxide, hydrogen peroxide and nitric oxide, which
then interact with DNA in proliferating epithelium. Although cells
respond to DNA damage by activating p53-controlled genes associated
with the cell cycle and DNA repair. In chronic inflammation, the rate
of ROS/RNS-mediated DNA damage is extensive, increasing the risk of
permanent genetic damage and lung cancer.14
Chronic persistent inflammation may also cause the usually quiescent
bronchoalveolar stem cells (BASCs) to proliferate and repopulate the
damaged areas in order to restore the lung architecture. This repeated
lung injury and repair driven by chronic inflammation and tissue
damage results in increased BASCs proliferation in conjunction with
smoking/inflammation-related genetic damage results in cancerous
transformation of lung epithelial cells. In a mouse model of
K-ras-induced carcinogenesis, BASCs give rise to lung adenocarcinoma.
Oncogenic KRAS stimulates the expansion of a cell population that
expresses stem cell markers at the region of bronchoalveoli duct junc-
tions, suggesting that these cells are precursors of lung adenocarci-
noma. Potentially, BASCs may be a key link between COPD and lung
cancer.15
Understanding the common processes/molecules that are central to
chronic inflammation and cancer may help identify novel therapeutic
strategies to prevent and treat lung cancer in addition to identifying
biomarkers to target those at high risk of developing lung cancer.
Proto-oncogene: the epidermal growth factor receptor family
and downstream signalling mediators
The epidermal growth factor receptor (EGFR) families are transmem-
brane tyrosine kinase receptors which induce cell proliferation and
enhance resistance to chemotherapy and radiotherapy. The EGFR
family EGFR1-4 also named HER1-4 are 59–81% homologous in the
tyrosine kinase domains. HER2 does not bind a specific ligand. HER2
is the preferred heterodimerization partner for other HER family recep-
tors. HER2-containing heterodimers are the most potent with regard to
downstream signalling activity. HER3 lacks kinase activity. Epiregulin
(which can be released by infected macrophages) binds to both the
EGFR and HER4. HER4 is overexpressed in NSCLC, correlates with
lymph node metastasis and occurs in early-stage disease.16
The EGFR1 and HER2 represent two of the most targeted oncopro-
teins in cancer with cetuximab, panitumumab, erlotinib and gefitinib
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all demonstrating clinical efficacy in phase III trials for the EGFR, and
trastuzumab (Herceptin) and lapatinib are FDA-approved against
HER2. EGFR mutations and gene overexpression invariably correlate
with a good tyrosine kinase inhibitor (TKI) response, whereas the con-
sequence of increased EGFR protein expression is conflicting. EGFR
mutations in the tyrosine kinase domain occur in 24% of NSCLCs and
are more frequently found in adenocarcinomas arising in never
smokers (58% compared with 13% in smokers), conferring approxi-
mately a 4-fold higher response rate to gefitinib and/or erlotinib.17
HER2 mutations occur in 2% of NSCLCs and appear to occur in the
same subpopulation as those with EGFR mutations. In NSCLCs par-
ticularly adenocarcinomas, EGFR is overexpressed in 70% and HER2
in 30% of patients but both are rarely expressed in SCLC.18 In con-
trast, HER4 mutations tend to occur in males and smokers.
EGFR TKI as first-line treatment in never smokers causes longer
progression-free survival compared with a standard platinum-based
chemotherapy.19 Strong evidence recommends against the use of gefiti-
nib or erlotinib in combination with chemotherapy or as maintenance
therapy after chemotherapy and radiation as a first-line treatment. The
phase III INTEREST study showed that gefitinib in unselected, pre-
treated patients, improved quality of life, reduced toxicity with equival-
ent overall survival compared with docetaxel chemotherapy. The phase
III IPASS study found improved progression-free survival with gefitinib
compared with paclitaxel–carboplatin chemotherapy in chemotherapy-
naive, never/light ex-smokers with adenocarcinoma. This and sub-
sequent prospective studies showed that patients with EGFR mutations
had longer progression-free survival and higher objective response rates
with gefitinib compared with chemotherapy.20 EGFR mutations are
found in histologically normal bronchial epithelial cells next to
tumours with EGFR mutations suggesting that EGFR mutation status
may be a useful early marker and chemoprevention target for lung
cancer.21
Approximately 30% of patients with EGFR mutations exhibit
primary resistance to EGFR TKI therapy. The mutation T790M in the
tyrosine kinase domain of EGFR may confer resistance to TKIs and is
also reported to be associated with familial NSCLC.22 MET amplifica-
tion is detected in 22% of lung cancer specimens that had developed
resistance to gefitinib or erlotinib. Met protein expression and phos-
phorylation is also associated with primary resistance to EGFR TKI
therapy in non-small-cell lung cancer patients harbouring EGFR
mutations.23 MET causes gefitinib resistance by driving HER3-
dependent activation of phosphatidylinositol-3 kinase (PI-3K). The
development of technology to detect EGFR mutations will help patient
selection in the future.
A. C. MacKinnon et al.
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The RAS/RAF/MEK/ERK pathway regulates downstream cellular
responses to growth factors and growth factor receptors and is upregu-
lated in many cancers. About 10–15% of NSCLCs have activating
RAS mutations, particularly adenocarcinoma, of which 20–30% have
RAS mutations and 90% of RAS mutations in lung cancers are KRAS
mutations, which activate MEK and ERK pathways.24 KRAS mutations
are more frequently found in adenocarcinomas arising in smokers,
21% compared with 4% in never smokers. In addition, EGFR and
KRAS mutations appear to be mutually exclusive. RAS mutations are
almost never found in SCLC. A number of drugs that target RAS func-
tion are in clinical trials. Farnesyl transferase inhibitors which are bioa-
vailable are in phase III clinical trials in lung cancer in combination
with cytotoxic drugs. The presence of KRAS mutation is a negative
predictor of response to TKIs, and the TRIBUTE trial suggests that
treating KRAS-mutated lung cancers with TKIs may be deleterious.25
Mutations of B-RAF a downstream effector of the RAS pathway occur
in 3% of non-small-cell lung cancers. Sorafenib is an orally adminis-
tered RAF kinase inhibitor. In phase II clinical trials, it has shown no
clear benefit in combination with carboplatin/paclitaxel in first-line
NSCLC. Activated B-RAF phosphorylates and activates MEK1 and
MEK2 which in turn phosphorylates and activates ERK1 and 2. ERK1
and 2 are constitutively activated in a subset of lung cancer cell lines
and are therefore therapeutic targets for lung cancer treatment. An oral
MEK inhibitor, CI-1040 lacked efficacy in a clinical trial for lung
cancer; however, its low toxicity has stimulated further research to find
novel compounds with enhanced potency against MEK.25
The PI-3K/AKT/PTEN pathway links lipid kinase and tyrosine kinase
pathways and is a key regulator of cancer growth, metastasis and treat-
ment failure. PI-3K is constitutively activated in NSCLC and SCLC cell
lines. A PI-3K inhibitor LY294002 enhances the sensitivity of lung
cancer cell lines to chemotherapeutic agents and radiotherapy and may
be useful as a cytotoxic or chemosensitizing agent. Activating
mutations of the catalytic subunit of PI-3K occur in 3% of
non-small-cell lung cancers. The tumour suppressor gene Phosphatase
and Tensin homologue deleted on chromosome 10 (PTEN) is a nega-
tive regulator of the downstream effector of PI-3K, AKT. PTEN is
rarely mutated in lung cancers but reduced or lost PTEN protein
expression is common in lung cancers, resulting in activation of the
AKT pathway. Mammalian target of rapamycin (mTOR) is a down-
stream effector of AKT kinase, and mTOR inhibitors such as sirolimus
and its derivatives are now in clinical trials for lung cancer.26
Although fusion proteins are rare in the pathogenesis of lung cancer,
a gene fusion between echinoderm microtubule-associated protein-like
4 and the anaplastic lymphoma kinase (ALK) gene occurs in 7% of
Advances in lung cancer biology
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NSCLCs, resulting in an activation of a potent ALK fusion protein,
which is usually found in never smoker with adenocarcinoma. This
ALK fusion protein may play a role in activating RAS and is negatively
associated with KRAS or EGFR mutations.27
BRCA1 is central to the repair of DNA damage and is an important
modulator of the response to chemotherapy. Retrospective and pro-
spective data indicate that low BRCA1 mRNA levels predict better
response and survival when patients are treated with cisplatin, non-
taxane combinations.28
BCL2 protects cells against apoptosis. BCL2 is overexpressed in 10–
35% of NSCLC and 75–95% of SCLC. Inhibitors of BCL2, BCL-XL
and BCL-w have anti-lung cancer activity in the mouse xenograft
models. However, surprisingly BCL2 expression and BAX, a
BCL2-related protein, correlate with a good prognosis in SCLC, and
clinical trials of anti-BCL2 agents in combination with the standard
chemotherapy regimens did not improve the clinical outcome.29
Cell-cycle regulation
p53 has been described as the guardian of the genome and is one of
the earliest mutations seen during lung carcinogenesis, leading to
genetic instability. p53 is a transcription factor, located on chromo-
some 17p13.1. Cytotoxic injury from DNA damaging agents or
hypoxia causes stabilization of the p53 protein leading to the
expression of cell-cycle arrest genes, allowing either DNA repair or the
initiation of apoptosis. Ninety percent of SCLCs and 50% of NSCLCs
have inactivating mutations of the p53 gene. TP53 mutations are more
commonly found in smokers compared with never smokers who
develop adenocarcinoma, 71% compared with 48%, respectively.
TP53 mutation patterns are different in lung cancers arising in smokers
and never smokers. G:C to T:A and A:T to G:C at CpG sites are more
common in smokers, 45% compared with 10% in never smokers. In
contrast, G:C to T:A at non-GpC sites is more common in never
smokers, 29% compared with 4% in smokers.30 Re-expressing a wild-
type p53 in lung cancer cells induces apoptosis. Clinical trials of p53
gene replacement therapy have demonstrated the feasibility and safety
of gene therapy and showed evidence of anti-tumour activity in a
number of cancers including lung cancer.31
The pRb(retinoblastoma)/p16 pathway plays an essential role in
tumour suppression in lung epithelium. In the hypophosphorylated
state, pRb is active and carries out its role as tumour suppressor by
inhibiting cell-cycle progression. Hyperphosphorylation by the cyclin
D1/CDK4 inactivates pRb, during the M-to-G1 transition. Loss or
A. C. MacKinnon et al.
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mutation of Rb is found in 15–30% of NSCLCs and over 90% of
SCLC.32 p16INK4a prevents CDK4 from phosphorylating RB. The loss
of p16INK4a function results in hyperphosphorylation and inactivation
of pRb. p16INK4a is inactivated by mutations, homozygous deletions
and promoter hypermethylation in 70% of NSCLCs. Aberrant
p16INK4a promoter DNA methylation can be found in sputum or exfo-
liated lung cells very frequently in lung cancer patients and among
disease-free smokers correlates only with very heavy smoking (.50
pack years) and therefore might be a useful biomarker.33 Cyclin D1 is
overexpressed in over 40% of NSCLCs. Overexpression of cyclin D1 in
histologically, normal bronchial epithelium in non-small-cell lung
cancer patients is associated with cigarette smoking and shorter survi-
val. Thus, cyclin D1 may be a useful biomarker to identify high-risk
subjects.34
Neuropeptide growth factors in small-cell lung cancer
SCLCs secrete many hormones and vasoactive peptides such as gastrin-
releasing peptide (GRP) and vasopressin. Patients present with syn-
dromes related to ectopic hormone secretion such as inappropriate
anti-diuretic hormone secretion and high levels of vasopressin in serum
predicts a poorer prognosis in patients with SCLC. Multiple neuropep-
tides act as growth factors and drive the unrestrained proliferation of
SCLC cells. The expression of these neuropeptide receptors increases as
cells become resistant to chemotherapy. 2A11 a monoclonal antibody
that binds GRP preventing receptor interaction has been shown to
inhibit the growth of SCLC in vitro and in xenografts in nude mice.
Analogues of substance P, such as [Arg6, D-Trp7,9, NmePhe8]-substance
P (6–11) (SP-G), bind to multiple neuropeptide receptors on SCLC
cells and block the mitogenic effects of neuropeptides and inhibit the
growth of SCLC cells in vitro and in vivo. SP-G has been shown to sen-
sitize SCLC cells to chemotherapy and may have an additional benefit
in resistant disease. SP-G has been taken into phase I clinical studies
for SCLC where therapeutic plasma levels were achieved with no dose
limiting toxicity.35
Cell adhesion-mediated drug resistance
Evidence suggests that the development of chemoresistance in SCLC
results from interactions between SCLC cells and extracellular matrix
(ECM) in the local tumour microenvironment. Fibronectin, collagen IV
and laminin are found in the stroma around the areas of tumour
Advances in lung cancer biology
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infiltration. Adhesion of SCLC cells to these ECM proteins stimulates
b1 integrin-mediated PI3-kinase activation, which prevents chemother-
apy (and radiation)-induced cell-cycle arrest and apoptosis despite per-
sistent DNA damage. ECM promotes SCLC cell survival during
chemotherapy and radiotherapy. Thus, blocking b1 integrin or its
downstream signals may be a novel therapeutic strategy to improve
responses to chemotherapy and radiotherapy. Clinical studies have
shown that high levels of ECM proteins around SCLC or high
expression of b1 integrins on SCLC cells predict a poor prognosis with
significantly shorter survival. This may potentially be used as a marker
to select SCLC patients for more intensive treatment.36
Vascular endothelial growth factor
Tumour growth beyond 2 mm3 requires angiogenesis and the amount
of angiogenesis, as measured by microvessel density, significantly corre-
lates with metastasis and poor survival in lung cancer. Lung cancers
produce high levels of VEGF. Bevacizumab is a monoclonal antibody
that neutralizes all VEGF isoforms and has been tested in clinical trials.
The combination of bevacizumab with paclitaxel and carboplatin pro-
vided a significant survival advantage in advanced adenocarcinoma.37
Serious life threatening side effects due to haemorrhage have been
observed. ZD6474 is a dual inhibitor of the VEGF receptor, and EGFR
and a phase 2 clinical trial using the combination of ZD6474 and doc-
etaxel as a second-line therapy showed an improved progression-free
survival in patients with advanced disease.38
Immune responses in lung cancer
Immune responses play an important role in the development of
cancers. Patients who are immunosuppressed are at greater risk of
developing cancer. Spontaneous tumour regression suggests that
tumours can be rejected by immunological responses. Lung cancers
escape immune surveillance by expressing FAS ligand, which causes
apoptosis of activated T-cells. In lung cancer cells, there is also downre-
gulation of the major histocompatibility complex class 1 molecule, pre-
venting the presentation of endogenous antigen peptides to cytotoxic
T-cells. Vaccination for lung cancer is difficult because of the poor
antigenic properties of lung cancer.
A. C. MacKinnon et al.
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Lung cancer stem cells
Cancer stem cells divide asymmetrically giving rise to another cancer
stem cell, and a cancer progenitor cell that contributes to the tumour
cell population. It is proposed that cancer stem cells may be responsible
for resistance to chemotherapy and radiotherapy because of their low
proliferation rate and the cell surface expression of drug transporters.
Increased numbers of stem cells confers a worse prognosis in haemato-
logical malignancies, breast and CNS tumours. However, in lung
cancer, there is as yet no definitive evidence for cancer stem cells.
Further evidence is required to prove their existence and define the phe-
notype of lung cancer stem cells, which may prove to be important
therapeutic targets to treat and eradicate residual disease.
Genetic factors in lung cancer
Genetic factors may influence a person’s susceptibility to lung cancer.
A family history of lung cancer, after controlling for cigarette smoke, is
associated with a 2-fold increased risk of lung cancer with evidence of
risk related to early age of diagnosis and number of relatives affected.39
A large-scale linkage analysis suggested that 6q23-25 is a major auto-
somal susceptibility locus for inherited lung cancer. This region con-
tains many genes potentially involved in the development of lung
cancer.40 Common polymorphisms in this region could be used to
identify people who may be suitable for smoking cessation and screen-
ing programmes.
Lung cancers show genetic instability which results in losses or gains
of whole or large portions of chromosomes. The exact causes of chro-
mosomal instability are uncertain but may be due to mutations in
mitotic checkpoint genes. Another form of chromosomal instability is
microsatellite instability that results in DNA sequence changes. Altered
DNA sequences either microsatellite instability or loss of heterozygos-
ity can be found in 43% of blood samples from patients with stage 1
lung cancer. No alterations were found in control cases suggesting that
this may be a useful tool for early diagnosis and screening.41
Epigenetic changes are common in lung cancer. Hypermethylation of
cytosine in clusters of CpG dinucleotides in the DNA promotor
sequence of protein-coding genes can lead to the loss of gene
expression. In lung cancer, over 80 genes are hypermethylated includ-
ing tumour suppressor genes, e.g. p16INK4a. Detecting methylated
DNA in sputum or blood may be a useful biomarker for early detec-
tion of lung cancer. Studies have shown that detecting three or more
Advances in lung cancer biology
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methylated genes from a panel of six selected genes correlated with a
6.5-fold increase in lung cancer with a sensitivity and specificity of
64%.42 In addition, another epigenetic change that inhibits gene
expression is histone deacetylation. Promotor methylation and histone
deacetylation are reversible processes; thus, pharmacological inhibition
is a potential novel therapeutic strategy that may reverse gene silencing
and thus be efficacious in lung cancer.
Repetitive TTAGGG telomere sequences localized at the end of mam-
malian chromosomes protect chromosomes from degradation.
Telomeres shorten after each round of cell division, limiting the life
span of the cell. Telomerase maintains telomeres by elongating telo-
meric DNA by reverse transcription. Upregulation of telomerase is
thought to contribute to early immortalization of cells, and telomerase
is upregulated in 80% of NSCLCs and nearly 100% of SCLCs. In
NSCLCs, high telomerase activity correlates with high proliferation
rates and advanced stage. GRN163L (imetelstat), a telomerase antag-
onist inhibits growth in vitro and in vivo of lung cancer cells and may
block cancer stem cells, is about to enter phase II clinical trials in lung
cancer.43
Lung cancer classification based on microarray gene expression pro-
files match conventional histological classification and correlate with
patient survival. This may help target patients at high risk of recurrence
who may benefit from adjuvant chemotherapy. Gene expression pro-
files from human airway epithelial cells identify 100 genes differen-
tially expressed between current and never smokers. Expression of
potential tumour suppressor genes and oncogenes persist after smoking
cessation, which may account for the fact that 50% of all lung cancer
cases occur in ex-smokers. Models that integrate clinical data and mul-
tiple gene expression profiles are significantly better at predicting recur-
rence than those using clinical data only. Combining cytopathology
and gene expression profiles improves the diagnostic sensitivity of lung
cancer to 95% with 95% negative predictive value.44 Thus, microarray
is an exiting new tool to classify lung cancers and predict prognosis
and response to treatments. Next-generation sequencing technologies
have recently sequenced two lung cancer genomes revealing the muta-
tional processes, repair pathways and gene networks associated with
lung cancer development. First, the genome of an SCLC cell line
derived from a bone marrow45 and second comparing a primary lung
adenocarcinoma with adjacent normal tissue.46 Both showed mutation
signatures characteristic of tobacco carcinogens. A total of 22 910–
50 000 point mutations were identified with an estimated genome-wide
somatic mutation rate of 17/Mb, some of which may be partially
redundant. Further sequencing will identify recurrent lung cancer
initiating mutations.
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Summary
Further research is required to identify the markers for early detection
and validate screening methods for patients at high risk of lung cancer.
In addition, identifying genetic and biological factors that predict
response to conventional and novel biological therapies and stratify
patients into high-risk groups requiring further intensive therapy is
required. Understanding the molecular and biological mechanisms that
drive the initiation and progression of lung cancer have already ident-
ified and will in the future identify further targets. Drug resistance
limits the current therapeutic approaches. Characterization of the
mechanisms that lead to the acquisition of drug resistance, in addition
to the evaluation of lung cancer stem cells, will help develop strategies
to combat drug resistance. It is possible that with further validation of
predictive biomarkers and tumour genetic signatures, it will be possible
to specifically tailor treatment decisions in individual lung cancer
patients. Ultimately, greater understanding of the molecular events that
drive lung cancer and genetic mutations that determine sensitivity to
conventional and targeted therapies may allow lung cancers to become
a chronic disease with relapses and remissions with which patients can
have prolonged survival.
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